Healthcare
Ocular Therapeutix, Inc.(OCUL)
Live Price
Offline$9.43
-2.18% today
1Y Change
+2.61%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $2.05B
- Revenue Growth
- -18.7%
- EPS Growth
- -16.4%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Ocular Therapeutix, Inc. (OCUL) is a Healthcare stock with a market cap of $2.05B and listed on NASDAQ. The stock last traded around $9.43 and up 2.6% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of -18.7%, EPS growth of -16.4%, a dividend yield of 0.0%. What stands out right now is revenue -18.7%, EPS -16.4%, free cash flow -59.5% with operating margin -519.8% and ROIC -35.5%. Valuation already assumes a fairly strong business story at price/sales 39.5. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines OCUL price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-18.7% vs +7.6% peer median
Operating Margin
Below sector median
-519.8% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 4, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -18.7% and EPS is at -16.4%, with operating margin around -519.8%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -0.1% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 4, 2026 | โ | -0.6% | -5.0% | -14.9% |
2026 Feb 5, 2026 | +12.1% | +2.8% | +1.7% | +15.3% |
2025 Nov 4, 2025 | +5.1% | -0.8% | +2.9% | +5.1% |
Benchmark Edge
OCUL vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
OCUL
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
OCUL Max Drawdown
-57.29%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for OCUL and SPY.
Company Overview
Ocular Therapeutix, Inc.
NASDAQ Global Market
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
- Leadership
- Pravin U. Dugel
- IPO Date
- Jul 25, 2014
- Employees
- 274
- Street Address
- 24 Crosby Drive
- Mailing
- Bedford, MA, 01730
- Region
- Bedford, MA, US
- Reporting Currency
- USD
- Investor Line
- 781 357 4000
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 39.5
- Price/Book
- 3.2
Growth
- Revenue
- -18.7%
- EPS
- -16.4%
- Free Cash Flow
- -59.5%
Profitability
- Gross Margin
- 87.3%
- Operating Margin
- -519.8%
- Net Margin
- -511.9%
- ROE
- -71.7%
- ROIC
- -35.5%
Balance Sheet
- Debt/Equity
- 0.12
- Current Ratio
- 15.39
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.